Clin Mol Hepatol.  2018 Dec;24(4):351-357. 10.3350/cmh.2017.0063.

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

• Ko SY
• Choe WH

• KMID: 2433297
• DOI: http://doi.org/10.3350/cmh.2017.0063

Abstract

The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few side effects and no comorbidities in the general population. Until recently, ideal DAA regimens have not been available to patients with severe renal impairment and end-stage renal disease because there are limited data on the pharmacokinetics, safety, and efficacy of treatment in this unique population. In a hemodialysis context, identifying patients in need of treatment and preventing HCV transmission may also be a matter of concern. Recently published studies suggest that a combination of paritaprevir/ritonavir/ombitasvir and dasabuvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir successfully treats HCV infection in chronic kidney disease stage 4 or 5 patients with or without hemodialysis.

Keyword

Chronic Hepatitis C; Hemodialysis; Direct-acting antivirals

MeSH Terms

Antiviral Agents*
Comorbidity
Hepacivirus
Hepatitis C*
Hepatitis C, Chronic
Hepatitis*
Humans
Kidney Failure, Chronic
Pharmacokinetics
Renal Dialysis*
Renal Insufficiency, Chronic*
Antiviral Agents